aTyr Pharma (ATYR) AI Stock Analysis

• Market Cap: $84.86M
• Dividend Yield: N/A
• Average Volume (3M): 10.48M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.81
• Revenue Growth: -100.00%
• EPS Growth: 11.89%
• Country: US
• Employees: 56
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.22
• Shares Outstanding: 97,986,630
• 10 Day Avg. Volume: 4,858,160
• 30 Day Avg. Volume: 10,483,519
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 4.58
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.01K
• Enterprise Value/Ebitda: -5.62
• 1Y Price Target: $8.10
• Price Target Upside: 831.03% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 9

• Rating: 39 Underperform
• Price Target: $1.00 ▲(14.94% Upside)

The overall stock score for aTyr Pharma is primarily impacted by its challenging financial performance, characterized by ongoing losses and negative cash flows. Technical analysis further supports a bearish outlook with the stock trading below key moving averages and indicators signaling oversold conditions. The negative P/E ratio and lack of dividend yield also contribute to a weak valuation score.

Positive Factors

Proprietary Platform

The proprietary platform offers a competitive advantage by enabling unique therapeutic developments, potentially leading to new revenue streams through licensing and partnerships.

Manageable Debt Levels

Low debt levels provide financial flexibility and reduce risk, allowing the company to focus on R&D and strategic investments without significant financial strain.

Focus on Unmet Medical Needs

Targeting rare diseases and inflammatory conditions positions the company in niche markets with less competition and potential for high-impact therapies.

Negative Factors

Negative Cash Flows

Persistent negative cash flows indicate financial instability, limiting the company's ability to invest in growth opportunities and sustain operations without external funding.

Declining Revenue

Declining revenue suggests challenges in product commercialization and market penetration, potentially impacting long-term growth and profitability.

Sustained Negative Profitability

Ongoing losses and high expenses relative to revenue hinder financial health, requiring strategic changes to achieve profitability and shareholder value.

aTyr Pharma Business Overview & Revenue Model

Company Description

aTyr Pharma, Inc. is a biopharmaceutical company focused on developing innovative therapies based on its proprietary protein-based platform, which is derived from the study of tRNA synthetases. The company primarily operates in the biotechnology sector, targeting rare diseases and inflammatory conditions. Its lead product candidate, ATYR1923, is being developed for the treatment of pulmonary sarcoidosis and other related disorders, highlighting the company's commitment to addressing unmet medical needs through advanced biopharmaceutical solutions.

How the Company Makes Money

aTyr Pharma generates revenue primarily through the development and commercialization of its therapeutic candidates. The company may receive funding from government grants and research partnerships, as well as milestone payments from collaborations with pharmaceutical companies. Additionally, aTyr Pharma seeks to monetize its proprietary platform technology through licensing agreements with other biotech firms. The company is also focused on advancing its clinical trials to move products toward market approval, which can lead to revenue from product sales once therapies are commercialized.

aTyr Pharma Financial Statement Overview

Summary

aTyr Pharma is experiencing substantial financial challenges, with a negative net profit margin and ongoing operational losses. Despite a strong equity position and manageable debt levels, declining revenue and negative cash flows significantly impact the financial outlook.

Income Statement

aTyr Pharma's income statement shows significant challenges with sustained negative profitability. The gross profit margin was 100% in 2024 due to minimal revenue, but the company has a consistent negative net profit margin due to high expenses outweighing revenue, with a net income of -$64 million in 2024. Revenue growth was negative at -33.43% from 2023 to 2024, indicating a decline in sales. The EBIT and EBITDA margins are both negative, reflecting ongoing operational losses.

Balance Sheet

The balance sheet shows a moderate financial position for aTyr Pharma. The debt-to-equity ratio is relatively low at 0.19, suggesting manageable leverage. However, the return on equity (ROE) is negative due to substantial net losses impacting shareholder value. The equity ratio stands at 72.33%, indicating a strong equity position relative to total assets.

Cash Flow

Cash flow analysis for aTyr Pharma reveals ongoing operational cash deficits, with an operating cash flow of -$69 million in 2024. The free cash flow growth rate is negative at -84.64%. The operating cash flow to net income ratio is slightly above 1, indicating operating losses are closely aligned with net income losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	235.00K	353.00K	10.39M	0.00	10.46M
Gross Profit	-387.00K	235.00K	353.00K	8.69M	-1.30M	-6.84M
EBITDA	-69.28M	-66.37M	-52.18M	-44.71M	-32.47M	-14.64M
Net Income	-66.64M	-64.02M	-50.39M	-45.34M	-33.77M	-16.22M
Balance Sheet
Total Assets	101.53M	96.83M	120.65M	95.79M	115.54M	38.73M
Cash, Cash Equivalents and Short-Term Investments	17.22M	72.13M	98.17M	66.15M	107.91M	31.69M
Total Debt	12.68M	13.28M	15.10M	11.53M	1.38M	2.24M
Total Liabilities	26.88M	27.00M	30.18M	24.50M	6.41M	7.24M
Stockholders Equity	74.84M	70.02M	90.66M	71.46M	109.30M	31.65M
Cash Flow
Free Cash Flow	-55.65M	-69.18M	-37.44M	-43.53M	-33.27M	-15.50M
Operating Cash Flow	-55.60M	-69.12M	-33.22M	-41.89M	-33.08M	-15.30M
Investing Cash Flow	10.74M	17.23M	-20.13M	47.24M	-91.57M	6.90M
Financing Cash Flow	55.26M	39.86M	66.23M	5.45M	110.03M	16.14M

aTyr Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATYR, the sentiment is Negative. The current price of 0.87 is below the 20-day moving average (MA) of 0.97, below the 50-day MA of 2.28, and below the 200-day MA of 3.71, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 30.01 is Neutral, neither overbought nor oversold. The STOCH value of 8.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATYR.

aTyr Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	―	$84.20M	-0.76	-69.96%	―	-99.64%	-59.17%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATYR	―	$84.86M	-1.09	-85.18%	―	-100.00%	11.89%
OKYO	―	$103.05M	―	―	―	―	―
CNTX	―	$97.78M	―	-37.25%	―	―	62.83%
PRLD	―	$67.35M	―	-96.33%	―	―	7.72%

aTyr Pharma Corporate Events

Atyr Pharma’s Promising Study on Efzofitimod for SSc-ILD: Key Insights for Investors

Study Overview: Atyr Pharma Inc. is conducting a study titled ‘Randomized, Double-blind, Placebo-controlled Proof-of-Concept (PoC) Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD).’ The study aims to assess the efficacy, safety, and tolerability of efzofitimod in treating SSc-ILD, a condition that affects lung function and skin. This research is significant as it explores new treatment avenues for a challenging disease.

aTyr Pharma Reveals Phase 3 Study Results

On September 15, 2025, aTyr Pharma announced the topline results from its Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis. The study did not meet its primary endpoint of reducing the mean daily oral corticosteroid dose, but showed clinical improvement in the King’s Sarcoidosis Questionnaire-Lung score and maintained lung function. The company plans to engage with the FDA to discuss the results and determine the next steps for efzofitimod’s development, highlighting its potential activity across multiple efficacy endpoints.

The most recent analyst rating on (ATYR) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on aTyr Pharma stock, see the ATYR Stock Forecast page.

aTyr Pharma Reports Q2 2025 Financial Results

aTyr Pharma Inc., a clinical-stage biotechnology company, focuses on developing innovative therapies for fibrosis and inflammation by leveraging tRNA synthetase biology. In its latest earnings report for the quarter ending June 30, 2025, aTyr Pharma highlighted its continued efforts in advancing its lead therapeutic candidate, efzofitimod, which is in clinical development for treating interstitial lung disease (ILD).